

THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
CENTERS FOR DISEASE CONTROL AND PREVENTION
NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

convenes

MEETING 55

ADVISORY BOARD ON
RADIATION AND WORKER HEALTH

The verbatim transcript of the 55th
Meeting of the Advisory Board on Radiation and
Worker Health held telephonically on May 14, 2008.

STEVEN RAY GREEN AND ASSOCIATES
NATIONALLY CERTIFIED COURT REPORTERS
404/733-6070

C O N T E N T S

May 14, 2008

WELCOME AND OPENING COMMENTS	7
DR. PAUL ZIEMER, CHAIR	
DR. CHRISTINE BRANCHE, DESIGNATED FEDERAL OFFICIAL	
CONGRESSIONAL LETTER CONCERNING CHAPMAN VALVE	11
CONGRESSIONAL LETTER CONCERNING TEXAS CITY CHEMICAL	15
CONGRESSIONAL LETTER CONCERNING ROCKY FLATS	18
SUBCOMMITTEE ON DOSE RECONSTRUCTION UPDATE	22
WORK GROUP UPDATES	26
SELECTION OF BOARD CONTRACTOR	55
TRACKING SYSTEMS	56
REVIEW LOCKEY VOTES FROM APRIL MEETING	67
MALLINCKRODT VISIT	69
COURT REPORTER'S CERTIFICATE	74

TRANSCRIPT LEGEND

The following transcript contains quoted material. Such material is reproduced as read or spoken.

In the following transcript: a dash (--) indicates an unintentional or purposeful interruption of a sentence. An ellipsis (. . .) indicates halting speech or an unfinished sentence in dialogue or omission(s) of word(s) when reading written material.

-- (sic) denotes an incorrect usage or pronunciation of a word which is transcribed in its original form as reported.

-- (phonetically) indicates a phonetic spelling of the word if no confirmation of the correct spelling is available.

-- "uh-huh" represents an affirmative response, and "uh-uh" represents a negative response.

-- "*" denotes a spelling based on phonetics, without reference available.

-- (inaudible)/ (unintelligible) signifies speaker failure, usually failure to use a microphone.

-- "^" denotes telephonic failure.

P A R T I C I P A N T S

(By Group, in Alphabetical Order)

BOARD MEMBERS

CHAIR

ZIEMER, Paul L., Ph.D.
 Professor Emeritus
 School of Health Sciences
 Purdue University
 Lafayette, Indiana

DESIGNATED FEDERAL OFFICIAL

BRANCHE, Christine, Ph.D.
 Principal Associate Director
 National Institute for Occupational Safety and Health
 Centers for Disease Control and Prevention
 Washington, DC

EXECUTIVE SECRETARY

WADE, Lewis, Ph.D.
 Senior Science Advisor
 National Institute for Occupational Safety and Health
 Centers for Disease Control and Prevention
 Washington, DC

MEMBERSHIP

BEACH, Josie
 Nuclear Chemical Operator
 Hanford Reservation
 Richland, Washington

1 CLAWSON, Bradley
 2 Senior Operator, Nuclear Fuel Handling
 3 Idaho National Engineering & Environmental Laboratory

GIBSON, Michael H.
 President
 Paper, Allied-Industrial, Chemical, and Energy Union
 Local 5-4200
 Miamisburg, Ohio

GRIFFON, Mark A.
President
Creative Pollution Solutions, Inc.
Salem, New Hampshire

1 LOCKEY, James, M.D.
2 Professor, Department of Environmental Health
3 College of Medicine, University of Cincinnati

4 MELIUS, James Malcom, M.D., Ph.D.
5 Director
6 New York State Laborers' Health and Safety Trust Fund
7 Albany, New York

MUNN, Wanda I.
Senior Nuclear Engineer (Retired)
Richland, Washington

POSTON, John W., Sr., B.S., M.S., Ph.D.
Professor, Texas A&M University
College Station, Texas

PRESLEY, Robert W.
Special Projects Engineer
BWXT Y12 National Security Complex
Clinton, Tennessee

ROESSLER, Genevieve S., Ph.D.
Professor Emeritus
University of Florida
Elysian, Minnesota

SCHOFIELD, Phillip
Los Alamos Project on Worker Safety
Los Alamos, New Mexico

IDENTIFIED PARTICIPANTS

ADAMS, NANCY, NIOSH
ANIGSTEIN, BOB, SC&A
BROEHM, JASON, CDC WASHINGTON OFFICE
BURGOS, ZAIDA, NIOSH
ELLIOTT, LARRY, NIOSH
HOWELL, EMILY, HHS
KOTSCH, JEFF, DOL
MAKHIJANI, ARJUN, SC&A
MAURO, JOHN, SC&A
NETON, JIM, NIOSH

P R O C E E D I N G S

(11:00 a.m.)

WELCOME AND OPENING COMMENTS**DR. PAUL ZIEMER, CHAIR****DR. CHRISTINE BRANCHE, DFO**

1 **DR. BRANCHE:** Welcome to the 55th meeting of
2 the Advisory Board on Radiation and Worker
3 Health. It is Wednesday, May 14th. This is a
4 telephone conference for the Board. I am
5 Christine Branche. I'm the designated federal
6 official and have the pleasure of serving you
7 in that role today.

8 Mr. Ray Green, are you up and
9 functioning?

10 **COURT REPORTER:** Yes, we're going.

11 **DR. BRANCHE:** Thank you.

12 Dr. Ziemer, if it's okay with you,
13 I'll simply do a quick, informal, rather I'll
14 do a formal roll call and then hand it over to
15 you.

16 **DR. ZIEMER:** That will be great. Thank you.

17 **DR. BRANCHE:** Josie Beach.

18 **MS. BEACH:** Here.

19 **DR. BRANCHE:** Brad Clawson.

20 **MR. CLAWSON:** Here.

1 **DR. BRANCHE:** Michael Gibson.

2 **MR. GIBSON:** Here.

3 **DR. BRANCHE:** Mark Griffon.

4 **DR. MELIUS:** Mark may be a little bit late.
5 This is Jim Melius, but I just talked to him
6 about something else, and he said he'd be on,
7 but he had a, he'd catch up with us in a
8 little bit.

9 **DR. BRANCHE:** Okay, thank you.

10 James Lockey.

11 **DR. LOCKEY:** Here.

12 **DR. BRANCHE:** And we just heard from Dr.
13 Melius.

14 Ms. Munn.

15 **MS. MUNN:** Yes.

16 **DR. BRANCHE:** Robert Presley.

17 **MR. PRESLEY:** Here.

18 **DR. BRANCHE:** John Poston.

19 **DR. POSTON:** Here.

20 **DR. BRANCHE:** Gen Roessler.

21 **DR. ROESSLER:** Here.

22 **DR. BRANCHE:** Phil Schofield.

23 **MR. SCHOFIELD:** Here.

24 **DR. BRANCHE:** Thank you very much. We have
25 a quorum, Dr. Ziemer.

1 I would ask that everyone
2 participating by phone please mute your phone
3 until you're ready to speak. You can use star
4 six to mute your phone if you do not have a
5 mute button. You would then use that same
6 star six to unmute your line when it is time
7 for you to speak. And apparently, there might
8 even be a new system that doesn't even allow
9 star six. And as soon as we find out what
10 that is, I'll pass that on to you. So thank
11 you very much for your participation today.

12 Let me just ask quickly, is there
13 anyone from NIOSH on the line, Larry Elliott
14 or Dave Sundin, are you on the line?

15 **DR. NETON:** This is Jim Neton. I'm on the
16 line. I think Larry intends to be. He might
17 be a little bit late though.

18 **DR. BRANCHE:** Thank you very much.

19 Dr. Ziemer, it's all yours.

20 **DR. ZIEMER:** Do we have any SC&A people on
21 the line?

22 **DR. MAURO:** Yes, Dr. Ziemer, this is John
23 Mauro.

24 **DR. ZIEMER:** Okay, thank you. Any others?

25 **DR. MAKHIJANI:** This is Arjun Makhijani.

1 **DR. ZIEMER:** Arjun, okay.

2 **DR. ANIGSTEIN:** Bob Anigstein.

3 **DR. ZIEMER:** Bob.

4 How about any O-R-A-U people?

5 (no response)

6 **DR. ZIEMER:** CDC?

7 **DR. BRANCHE:** Dr. Ziemer, would you like me
8 to go through the --

9 **DR. ZIEMER:** Yeah, yeah, for the record we
10 may need to --

11 **DR. BRANCHE:** All right. Is there anyone
12 from Oak Ridge on the line?

13 (no response)

14 **DR. BRANCHE:** What about other federal
15 agency staff?

16 **MS. HOWELL:** This is Emily Howell with HHS.

17 **DR. BRANCHE:** Thank you.

18 **MR. KOTSCH:** Jeff Kotsch from Labor.

19 **MR. BROEHM:** Jason Broehm, CDC.

20 **DR. BRANCHE:** Are there petitioners or their
21 representatives on the phone?

22 (no response)

23 **DR. BRANCHE:** Are there workers or their
24 representatives on the line?

25 (no response)

1 **DR. BRANCHE:** Are there any members of
2 Congress or their reps on the line?

3 (no response)

4 **DR. BRANCHE:** Are there any others who would
5 like to mention their name?

6 (no response)

7 **DR. ZIEMER:** Thank you very much, Christine.

8 **DR. BRANCHE:** Thank you.

9 **DR. ZIEMER:** And good morning everyone. I
10 assume everyone has a copy of the agenda which
11 was distributed to the Board members by e-
12 mail. And for members of the public it is
13 also available on the NIOSH/OCAS website. So
14 we will follow that agenda. The items have
15 estimated times, but I have a feeling we may
16 be able to streamline things a bit and perhaps
17 be able to get through the agenda a little
18 sooner than we have on the proposed or the
19 draft agenda. In any event, we'll move
20 forward item by item.

21 **CONGRESSIONAL LETTER CONCERNING CHAPMAN VALVE**

22 The first item on the agenda is a
23 response to the congressional letter from
24 Senator Kennedy, Kerry and Representative
25 Neal, and it concerns Chapman Valve. This was

1 a letter that I also distributed to the Board
2 members I think about a week or so ago. The
3 letter is dated April 2nd.

4 It indicates concern about progress on
5 the Chapman Valve petition. I have
6 distributed to the Board members a proposed
7 draft to respond to that letter. The draft --
8 and I want to make sure everyone's got a copy
9 of the draft. Any Board member did not
10 receive a copy of that draft?

11 (no response)

12 **DR. ZIEMER:** Apparently not. So it would be
13 appropriate, under our procedures a response
14 to congressional members requires Board
15 approval. So I would ask that there either be
16 a petition to approve this or I would call for
17 any additions, corrections or modifications of
18 this draft.

19 **MS. MUNN:** This is Wanda. I'm prepared to
20 move that the draft letter under the date of
21 May 14th that was received by way of e-mail be
22 accepted as written.

23 **DR. ZIEMER:** Well, thank you. Is there a
24 second?

25 **MR. PRESLEY:** This is Bob Presley. I

1 second.

2 DR. LOCKEY: Hey, Paul, Jim Lockey, one
3 comment. The second paragraph where it says
4 ER. I know what that stands for, but I would
5 just write it out.

6 DR. ZIEMER: Yes.

7 DR. LOCKEY: Okay.

8 DR. ZIEMER: Evaluation Report.

9 DR. LOCKEY: Yes, just write that out. It's
10 only used twice, and I'd write it out.

11 DR. ZIEMER: Thank you.

12 DR. ROESSLER: This is Gen.

13 DR. ZIEMER: I'll take that as a friendly
14 amendment.

15 DR. ROESSLER: This is Gen. I have a
16 comment in that same paragraph. Since we know
17 the dates of the meeting in St. Louis in June,
18 I think it would be helpful to put them in.

19 DR. ZIEMER: Yes, we can certainly do that,
20 Gen, and that would be -- I'm just looking up
21 the dates here myself.

22 DR. BRANCHE: The 24th through the 26th.

23 DR. ZIEMER: June 24th through the --

24 DR. BRANCHE: Twenty-sixth.

25 DR. ZIEMER: Twenty-sixth, right, I'll add

1 that if there's no objection.

2 (no response)

3 **DR. ZIEMER:** Any others?

4 (no response)

5 **DR. ZIEMER:** Okay, then let me ask then with
6 those friendly amendments are you ready to
7 vote on this? We'll have to vote by roll call
8 since we're on the phone.

9 Christine, if you'd proceed with the
10 roll call.

11 **DR. BRANCHE:** Are you ready now or do you
12 want to see if there are any other comments?

13 **DR. ZIEMER:** I'm assuming there are none
14 unless I hear something.

15 **DR. BRANCHE:** All right, I'll proceed then.

16 Ms. Beach.

17 **MS. BEACH:** Yes.

18 **DR. BRANCHE:** Mr. Clawson.

19 **MR. CLAWSON:** Yes.

20 **DR. BRANCHE:** Mr. Gibson.

21 **MR. GIBSON:** Yes.

22 **DR. BRANCHE:** Mr. Griffon.

23 (no response)

24 **DR. BRANCHE:** Dr. Lockey.

25 **DR. LOCKEY:** Yes.

1 DR. BRANCHE: Dr. Melius.

2 DR. MELIUS: Yes.

3 DR. BRANCHE: Ms. Munn.

4 MS. MUNN: Yes.

5 DR. BRANCHE: Mr. Presley.

6 MR. PRESLEY: Yes.

7 DR. BRANCHE: Dr. Poston.

8 DR. POSTON: Yes.

9 DR. BRANCHE: Dr. Roessler.

10 DR. ROESSLER: Yes.

11 DR. BRANCHE: Mr. Schofield.

12 MR. SCHOFIELD: Yes.

13 DR. BRANCHE: Dr. Ziemer.

14 DR. ZIEMER: Yes.

15 Thank you, and that motion carries. I
16 will make those minor changes and send off the
17 letter as amended.

18 **CONGRESSIONAL LETTER CONCERNING TEXAS CITY CHEMICAL**

19 I had one other one here. Hang on.
20 I'm trying to pull it out here. Although it
21 doesn't show on the agenda there was an
22 additional, actually two additional letters
23 that came in. One was -- I think I
24 distributed this one. Let me double check. I
25 received also a letter from Congressman

1 Lampson who is from Texas. And this one
2 concerned the Texas City Chemicals facility.
3 I believe I also distributed his letter and a
4 draft response. Did everyone receive that
5 one? Or is there anyone who did not receive
6 that?

7 (no response)

8 **DR. ZIEMER:** Okay, apparently not. I'm
9 taking the silence to mean that you have all
10 received it rather than that you can't hear me
11 or that you're offline.

12 I again would call for a motion to
13 accept and transmit this letter with any
14 modifications you may wish to make.

15 **DR. LOCKEY:** Jim Lockey. I so move.

16 **DR. ZIEMER:** Thank you. Second?

17 **MR. CLAWSON:** This is Brad Clawson, I move,
18 I second it.

19 **DR. ZIEMER:** Thank you. Any modifications
20 or recommendations for change?

21 **DR. LOCKEY:** Jim Lockey again, take out the
22 ER. You don't need it.

23 **DR. ZIEMER:** Thank you, friendly amendment,
24 right.

25 Any others?

1 (no response)

2 **DR. BRANCHE:** Dr. Ziemer, would you like to
3 do the roll call again?

4 **DR. ZIEMER:** If we're ready to vote, we'll
5 do so. Any other changes? Friendly amendment
6 just remove the ER since we only use the term
7 Evaluation Report in the first paragraph, no
8 need to abbreviate it there. It's not used
9 again.

10 And basically this is simply, he asks
11 for a response. We're basically saying we
12 will keep you updated on progress on this one
13 as well.

14 Okay, let's take the roll call on that
15 one.

16 **DR. BRANCHE:** Ms. Beach.

17 **MS. BEACH:** Yes.

18 **DR. BRANCHE:** Mr. Clawson.

19 **MR. CLAWSON:** Yes.

20 **DR. BRANCHE:** Mr. Gibson.

21 **MR. GIBSON:** Yes.

22 **DR. BRANCHE:** Mr. Griffon.

23 **MR. GRIFFON:** Yes.

24 **DR. BRANCHE:** So you've joined us, Mr.
25 Griffon.

1 MR. GRIFFON: I did. I just got on.

2 DR. BRANCHE: Wonderful.

3 Dr. Lockey.

4 DR. LOCKEY: Yes.

5 DR. BRANCHE: Dr. Melius.

6 DR. MELIUS: Yes.

7 DR. BRANCHE: Ms. Munn.

8 MS. MUNN: Yes.

9 DR. BRANCHE: Mr. Presley.

10 MR. PRESLEY: Yes.

11 DR. BRANCHE: Dr. Poston.

12 DR. POSTON: Yes.

13 DR. BRANCHE: Dr. Roessler.

14 DR. ROESSLER: Yes.

15 DR. BRANCHE: Mr. Schofield.

16 MR. SCHOFIELD: Yes.

17 DR. BRANCHE: Dr. Ziemer.

18 DR. ZIEMER: Yes.

19 Motion passes. Thank you very much, I
20 will send out that letter.

21 CONGRESSIONAL LETTER CONCERNING ROCKY FLATS

22 I also distributed, while we're doing
23 congressional letters, I believe the letter
24 that was received from Senator Salazar, that
25 letter was dated April 16th. I have not

1 drafted a response to that letter. It's not
2 clear to me that we need to respond at this
3 point. I would solicit the Board's advice on
4 that.

5 It appears that it is simply a
6 statement of concern about the situation at
7 Rocky Flats, and that it seems to be more
8 directed to the Secretary of Labor and the
9 Secretary of Health and Human Services in
10 terms of how they are implementing the
11 recommendation of the Board. But I would
12 solicit the advice of the Board members as to
13 whether you believe we as a Board should
14 respond to this letter.

15 And if you believe we should, then I
16 may need to have a more detailed draft
17 prepared. And we may not be able to act on
18 that today, but I did want to get feedback on
19 that issue.

20 **MS. MUNN:** This is Wanda. I agreed with
21 your assessment when I read the letter. It
22 obviously is requesting feedback from Labor,
23 especially Labor, as well as NIOSH. But it
24 doesn't appear obvious if there's any response
25 that we can give.

1 **DR. ZIEMER:** Thank you for that comment.

2 Any others? One or the other.

3 **MR. GRIFFON:** Paul.

4 **DR. ZIEMER:** Yes.

5 **MR. GRIFFON:** This is Mark Griffon. I think
6 we should at least, I don't know that we need
7 a letter response, but I think we should
8 communicate with their office that I am
9 planning a work group meeting, and I was going
10 to give that in my work group update. But we
11 are going to invite as per the previous Board
12 meeting, I'm going to invite the Department of
13 Labor to discuss the implementation of the
14 class with the work group. And I'm also going
15 to have Margaret Ruttenber, if she's
16 available, from the University of Colorado on
17 that meeting to be involved with her
18 expertise.

19 **DR. ZIEMER:** Have you set a date on that one
20 yet, Mark?

21 **MR. GRIFFON:** I haven't. I want to get it
22 in before the St. Louis meeting, but it's
23 going to be phone call meeting. It's not
24 going to be a face-to-face, so it should be a
25 little easier to schedule.

1 **DR. ZIEMER:** Well, what I'm wondering, again
2 even if it's a piece of information, if the
3 Board would like me to transmit that to the
4 Senator's office, I will be glad to do that,
5 but I need instruction from the Board to do
6 so.

7 **DR. LOCKEY:** Jim Lockey, I think it's a good
8 idea that you at least respond that you got
9 the letter, and I think that's appropriate.

10 **DR. ZIEMER:** And that Mark is going to have
11 this meeting?

12 **DR. LOCKEY:** Yes.

13 **MR. GRIFFON:** Yeah, through the e-mail I'll
14 even give you a date, and if you want to
15 include that in your letter --

16 **DR. ZIEMER:** Okay. Let me see if there's
17 any objection on the part of any Board members
18 to responding to the letter informationally
19 indicating that this meeting will take place.

20 **MS. MUNN:** Just to allow them to know that
21 we're continuing.

22 **DR. ZIEMER:** Right, any objections?

23 **MR. PRESLEY:** No problem, Paul.

24 **DR. ZIEMER:** If there's no objection, if
25 you'll allow Mark and me to prepare the

1 letter, we will copy everyone on it and,
2 again, it will be a response that indicates
3 what the plans are for the work group to at
4 least in part address this issue. Is that
5 agreeable?

6 **DR. LOCKEY:** I so move.

7 **DR. ZIEMER:** Okay, we'll take it as a
8 motion. Second?

9 **MR. PRESLEY:** Presley.

10 **DR. ZIEMER:** Presley seconds. I'll do it
11 easily. Are there any objections? Anyone
12 who'd would vote no on the motion?

13 (no response)

14 **DR. ZIEMER:** Any abstentions?

15 (no response)

16 **DR. ZIEMER:** Then the motion carries. Thank
17 you. It will take care of those three
18 congressional letters then.

19 **SUBCOMMITTEE ON DOSE RECONSTRUCTION UPDATE**

20 Now let's move on. Subcommittee on
21 Dose Reconstruction updates. Or update on
22 Subcommittee on Dose Reconstruction. Mark,
23 are you ready to update us?

24 **MR. GRIFFON:** Yeah, I don't have much of an
25 update. We do, I just coordinated with the

1 subcommittee members and with Christine
2 Branche on setting a subcommittee, a next
3 meeting that's going to be on June 10th in
4 Cincinnati. We wanted to have it prior to the
5 St. Louis meeting rather than in conjunction
6 with the St. Louis meeting. I don't know --

7 Paul, maybe you can help me. I don't
8 know if the last letter report actually got
9 submitted yet or --

10 **DR. ZIEMER:** No, let's see, the last letter
11 report which is cases 61 through 100, Mark, I
12 sent you --

13 **DR. BRANCHE:** Excuse me, Dr. Ziemer, you're
14 fading.

15 **MR. GRIFFON:** Yeah.

16 **DR. ZIEMER:** Oh, I am on a land line. Maybe
17 I'm just fading anyway.

18 **DR. BRANCHE:** We can hear you much better
19 now. Thank you.

20 **DR. ZIEMER:** I prepared a draft, from the
21 subcommittee's last draft I prepared a
22 letterhead draft, Mark, made a few editorial
23 changes. I sent you that about a week ago.

24 **MR. GRIFFON:** Okay, I'm sure I have it.
25 I've got a lot of e-mails from you.

1 **DR. ZIEMER:** Now what we need, there's some
2 numbers that we need, and I think we're going
3 to need them from NIOSH. I'll give Jim Neton
4 a heads up. In that report we give the number
5 of cases that were complete at the time that
6 those two sets of 20 were selected. We don't
7 have those numbers.

8 **MR. GRIFFON:** Okay, I think Stu Hinnefeld
9 might have given those to me, but I'm maybe --

10 **DR. ZIEMER:** So those are still missing from
11 the final draft --

12 **MR. ELLIOTT:** Dr. Ziemer, this is Larry
13 Elliott. I'm sorry. I joined the call a
14 little late, but I've heard your comment
15 there.

16 And, Mark, if we, I'll touch base with
17 Stu, and we'll get you the numbers again.

18 **MR. GRIFFON:** That's fine.

19 **DR. ZIEMER:** There's two numbers, one for 60
20 through 80 and one number for 80 through 100.
21 It's the number of cases from which the
22 selection was made.

23 **MR. ELLIOTT:** Understood.

24 **DR. ZIEMER:** And then the only other thing I
25 need, we need to make sure that we have the

1 correct tables, SC&A tables, in the
2 attachments, but I'll work on that --

3 **MR. GRIFFON:** I'm sorry I didn't look at
4 that before the call here.

5 **DR. ZIEMER:** Yeah, I think as soon as we
6 have those two numbers everything is ready to
7 go in.

8 **MR. GRIFFON:** Okay. And other than that the
9 upcoming meeting we're going to be working on
10 the sixth and seventh set of cases, the
11 matrices, and I will circulate those to
12 subcommittee members hopefully a week in
13 advance of the meeting so people have time to
14 review them and prepare for the meeting. And
15 I think that's really all I have to update on
16 the subcommittee.

17 **DR. ZIEMER:** Thank you. The other thing I
18 think to note is that SC&A this past week, and
19 I think perhaps this week, is also working
20 with the individual teams on the eighth set.

21 **MR. GRIFFON:** Yes.

22 **DR. ZIEMER:** And some have already done
23 those, maybe all have finished by now. I
24 don't know.

25 **MS. MUNN:** No, we haven't.

1 **MR. GRIFFON:** We haven't.

2 **DR. ZIEMER:** Okay. I know Mike and I did
3 ours the other day, but those are in process.
4 So things are moving along well there.

5 So is there anything else on the Dose
6 Reconstruction Subcommittee, Mark? That's
7 pretty well it?

8 **MR. GRIFFON:** No, I think that's it at this
9 point.

10 **DR. ZIEMER:** Okay, very good.

11 **WORK GROUP UPDATES**

12 Okay, let's move on to work group
13 updates.

14 **DR. BRANCHE:** I'm ready to go through the
15 list whenever you're ready, Dr. Ziemer.

16 **DR. ZIEMER:** I'd like to do Chapman Valve at
17 the front end because at some point John
18 Poston may have to leave.

19 John, you're still here, right?

20 **DR. POSTON:** Yes, I'm still here.

21 **DR. ZIEMER:** And let's get Chapman Valve. I
22 think it's early on our list anyway, but let's
23 go ahead and start with Chapman and continue
24 from there.

25 **DR. POSTON:** Are you ready?

1 **DR. ZIEMER:** Uh-huh.

2 **DR. POSTON:** We had a face-to-face meeting
3 on May the 1st in Cincinnati to discuss the
4 Chapman Valve to try to resolve some issues.
5 We ended up with two or three things that are
6 still unresolved. Jim Neton was in contact
7 with the folks at Oak Ridge regarding the one
8 sample that showed an elevated level of
9 Uranium-235 ^ two percent, and we're waiting
10 to hear back from that.

11 We also composed a letter or produced
12 a list, let me say it that way, that was given
13 to, I think Jim also took responsibility for
14 this, the request of additional information
15 and clarification from the DOE regarding the
16 sites and what was going on at the sites and
17 so forth. And so far as I know, we don't,
18 haven't resolved either one of those since May
19 the 1st.

20 And then the third thing was that the
21 committee, the working group, decided that we
22 should recommend to the Board that we separate
23 the Chapman Valve into two pieces. It had
24 been put -- let me get my notes here so I get
25 it straight. We had the -- I can't think of

1 the right word. We added the --

2 **MR. GRIFFON:** Dean Street facility.

3 **DR. POSTON:** I'm sorry?

4 **MR. GRIFFON:** The Dean Street facility?

5 **DR. POSTON:** Right, yes. We added the Dean
6 Street facility, but we had been unable to
7 find any kind of information that will allow
8 us to consider the Dean Street facility with
9 the Chapman Valve facility that we were
10 evaluating. So our recommendation to the
11 Board is that we separate those out so we can
12 move forward with the original Chapman Valve
13 facility under the timeframe that we were
14 considering. Otherwise the Dean Street
15 facility may hold us up for an extremely long
16 time, and we don't want to do that. I think
17 that's pretty much it.

18 **DR. ZIEMER:** I'm wondering though from a,
19 let's say a legal point of view, and maybe
20 Emily or Liz could help us on this, but don't
21 we have to go with the definition as it's come
22 from Labor and as NIOSH is now using it?

23 **DR. POSTON:** I'm not sure who established
24 that definition.

25 **MS. HOWELL:** Right, the class definition

1 does not necessarily have to follow the entire
2 covered period as DOL defines it. And this
3 class definition came from NIOSH. As you'll
4 recall originally Dean Street was not
5 included, and then it was added in by NIOSH
6 after Dean Street was added to the covered
7 facility list by the Department of Energy.

8 So what we directed the working group
9 at the May 1st meeting was that splitting it
10 back out is fine, you know, if an additional
11 class could be considered for the Dean Street
12 facility if necessary. And I think that Jim
13 Neton and Larry were at that meeting and
14 indicated that they, too, were going to look
15 at NIOSH changing its evaluation report to
16 remove that as well.

17 **DR. ZIEMER:** So does this require any Board
18 action to make that separation in terms of
19 what our work group does?

20 **MS. HOWELL:** The work group can look at what
21 it likes to, but in terms of the Board, if the
22 Board is to vote on a class up or down, they
23 would need to make sure that the definition
24 that they're using includes what they want it
25 to.

1 **DR. ZIEMER:** So the work group could come to
2 us with two different pieces?

3 **MS. HOWELL:** Or one piece.

4 **DR. ZIEMER:** Or one and we could handle
5 those as we please.

6 **MS. HOWELL:** Yes.

7 **DR. POSTON:** We've just been, and when I say
8 we I mean the members of the working group and
9 NIOSH of course, just been unable to find any
10 documentation at all that says anything about
11 what's going on at the Dean Street facility.
12 And if we continue to pull that string, then
13 we're just delaying any kind of decision on
14 the other facility.

15 **DR. ZIEMER:** Understood. So you anticipate
16 then at our next full meeting that you will
17 come with a recommendation on the, everything
18 but the Dean Street then or --

19 **DR. POSTON:** Well, that's the plan. The
20 idea is to get the information from Oak Ridge
21 regarding how the soil samples were analyzed.
22 And certainly you could argue about this. My
23 recollection is there was only two soil
24 samples, and one didn't show any elevated
25 levels; the other did. So you can, you have

1 the question of which one is correct. But the
2 information we could get from Oak Ridge would
3 be very helpful for that, and also any
4 response to our request for additional
5 information from DOE would be helpful.

6 And then the ideal was to have a
7 conference call to try to resolve this. We're
8 not concerned about the external dosimetry,
9 the film badge results and so forth, we
10 believe are acceptable and useful in bounding
11 the external doses. The approach taken by
12 NIOSH to bound the internal doses is perfectly
13 fine if there's no enriched uranium present.
14 If there is enriched uranium present, which we
15 don't know for sure, then the internal dose is
16 double.

17 So that's the big hang up right now.
18 If they're dealing with natural uranium, then
19 the approach used by NIOSH is certainly
20 bounding the internal dose, and in my opinion
21 everything is satisfactory. I guess that's
22 the problem that we're facing right now.

23 **DR. ZIEMER:** So we'll look forward then to
24 some sort of recommendation at the June
25 meeting.

1 **DR. POSTON:** That's the goal.

2 **DR. ZIEMER:** And that's what we have told
3 Senator Kennedy and his other colleagues.

4 **DR. BRANCHE:** Shall we go through the list
5 now?

6 **DR. ZIEMER:** Yes.

7 **DR. BRANCHE:** Blockson Chemical special
8 exposure cohort, Ms. Munn, Chair.

9 **MS. MUNN:** We had identified a need for
10 another face-to-face meeting based on the two
11 outstanding concerns that have been voiced by
12 Dr. Melius and Mark Griffon in an attempt to
13 go through those items again to see whether an
14 actual consensus on a recommendation of the ^
15 agree with each other ^ reached. We had
16 established that 5th of June originally ^
17 polled the work group since that time to
18 identify if they are, in fact, going to be
19 able to meet that schedule. I have not had
20 back the written request that we had made
21 during our Board meeting that concerns the ^
22 put in writing and very clearly specified as
23 to where the focus is on those concerns. ^
24 involved in asking again for those ^ to be
25 specified blow by blow so that we will have ^

1 in front of us.

2 **DR. ZIEMER:** So you're shooting for a June
3 5th meeting of the work group?

4 **MS. MUNN:** That's the date that we had
5 originally ^ . I believe that announcement
6 actually has already ^ several weeks ago.

7 **DR. ZIEMER:** Okay, thank you.

8 Incidentally, as the chairs give their
9 reports if any members of any of the work
10 groups have anything to add, please feel free
11 to do that as we proceed. Let's go ahead
12 then.

13 **DR. BRANCHE:** Fernald site profile and
14 special exposure cohort petition, Mr. Clawson,
15 Chair.

16 **MR. CLAWSON:** We've met three times now. At
17 the last meeting we still had several issues
18 that we're going through. One of the things
19 is is NIOSH brought forth to be able to cover
20 some of the thorium and so forth by using
21 urine data. And so SC&A is looking into this
22 of how good our urine data is and so forth
23 like that.

24 And we're getting prepared to be able
25 to have another meeting. We don't have

1 anything scheduled yet, but NIOSH has a list
2 of things to do for the matrix, and we're just
3 going to try to, in the next month or so I'd
4 like to try to get everybody together again
5 and proceed with some of these issues and so
6 forth. That's about it.

7 **DR. ZIEMER:** Thank you.

8 **DR. BRANCHE:** Hanford site profile and
9 special exposure cohort petition, Dr. Melius,
10 Chair.

11 **DR. MELIUS:** I just had to unmute myself.
12 Actually not much to report. We've done some
13 technical coordination on access to data with,
14 between NIOSH, SC&A and NIOSH and DOE. And I
15 believe that it's moving along.

16 There was a quick technical conference
17 call this morning just before this meeting
18 that I was unable to participate in so I don't
19 know if Arjun or anybody have anything else to
20 report. But it's mainly just to try to
21 prioritize data requests to facilitate the
22 limited resources that DOE has to access data
23 and try to satisfy everybody.

24 I don't know, Arjun, if you have
25 anything to add, or Larry.

1 the work group, if not to others.

2 **DR. MELIUS:** Yeah, I will.

3 **DR. ZIEMER:** Thanks. Any other comments on
4 Hanford?

5 (no response)

6 **DR. ZIEMER:** Okay, thank you.

7 **DR. BRANCHE:** Los Alamos National Laboratory
8 site profile and special exposure cohort, Mr.
9 Griffon, Chair.

10 **MR. GRIFFON:** Yes, thank you. The only
11 thing I have to update on is I think our work
12 group is going to be delayed in meeting a
13 little bit more. I talked to LaVon Rutherford
14 yesterday, and they are working on the special
15 exposure cohort evaluation for the later time
16 period. I think it's from '75 on at Los
17 Alamos.

18 And in parallel they were updating the
19 site profile, but he said that they've made a
20 decision on some, obviously one impacts the
21 other. That they're going to focus on the
22 evaluation report and come back to the work
23 group with the evaluation report if that is
24 okay. And I indicated that I thought that was
25 a good path forward. And LaVon said that

1 probably would be an August/September
2 timeframe. They'll be probably pushing the
3 180 days to complete that. So we may not have
4 anything for awhile, but as soon as we get a
5 report, we'll schedule a meeting on that.

6 **DR. ZIEMER:** Thank you.

7 **DR. BRANCHE:** Linde Ceramics site profile,
8 Dr. Roessler, Chair.

9 **DR. ROESSLER:** This is Gen. Ray, can you
10 hear me better?

11 **COURT REPORTER:** Yes, Gen, thank you.

12 **DR. ROESSLER:** With regard to the Linde site
13 profile review, we have one remaining issue
14 that is being reviewed by SC&A of NIOSH's
15 approach for doing dose estimates for the
16 Linde workers who may have been near used
17 burlap bags containing ^ . And an interview
18 with a worker indicates that several pallets
19 of these used bags may have been present in or
20 behind Building 30 in 19^ . We were hoping to
21 hold a June 6th meeting of the work group
22 either by teleconference or in person, but we
23 have not received SC&A's review yet, so until
24 we get that, this meeting is up in the air.
25 As soon as we receive the report, then I will

1 get in touch with the work group and ^.

2 **DR. ZIEMER:** Okay.

3 **DR. BRANCHE:** Mound SEC petition, and Ms.
4 Beach, Chair.

5 **MS. BEACH:** Yes, Mound has not met since our
6 last meeting. We are working with SC&A and
7 NIOSH on action items from our first meetings,
8 and we'll be able to get together with the
9 work group to set priorities I'm hoping next
10 month or so. That's all I have.

11 **DR. ZIEMER:** Thank you. Good.

12 **DR. BRANCHE:** Nevada Test Site profile and
13 SEC petition, Mr. Presley, Chair.

14 **MR. PRESLEY:** This is Bob Presley. We have
15 a meeting coming up on the 21st of May to
16 discuss some issues. We have gone through the
17 matrix and have completed everything except
18 some TBDs that we're waiting to look at. The
19 only outstanding thing that we have is the
20 correction factors for the external
21 environmental dose due to the geometry of the
22 origin of the badge.

23 And SC&A is looking into some of the
24 items for that that they're going to present
25 hopefully at the meeting. But the internal

1 dose -- y'all excuse me. Wait a second now.
2 I'm at work. The NIOSH, when they checked
3 that 100 people ^ review, SC&A would like to
4 go back and look at some of those. And we've
5 got to decide at the Board, whether we want to
6 do any more work on that. SC&A pulled 53 of
7 those 100 cases, but they won't be ready to
8 make their report until around June the 4th.

9 So we're going to meet on the 21st and
10 hopefully we can saw some stuff off. If we
11 can't, we may have to have a short working
12 group meeting before the June meeting in St.
13 Louis. What I would like to do is everybody
14 think about maybe having something the night
15 of the 23rd like we did when we were in Las
16 Vegas. I know it's hard on everybody, but
17 depending on what comes up on the 21st of
18 whether we have this one on the 23rd.

19 **DR. BRANCHE:** Mr. Presley.

20 **MR. PRESLEY:** Yes, ma'am.

21 **DR. BRANCHE:** Mr. Presley, I can work with
22 you while we're in Cincinnati next week
23 because I haven't finalized the agenda for the
24 Board meeting in St. Louis. So there might be
25 more flexibility than you realize.

1 **MR. PRESLEY:** And we should know more after
2 the meeting on the 21st.

3 **MR. ELLIOTT:** Mr. Presley, this is Larry
4 Elliott.

5 **MR. PRESLEY:** Yes, sir.

6 **MR. ELLIOTT:** Just to add to this discussion
7 and for your work group's consideration, I had
8 a conversation by phone yesterday with Mr.
9 Funk from Nevada Test Site who's advocating
10 for many claimants there as you know. And he
11 asked me to make sure that I transmitted some
12 information he is providing. He's going to
13 overnight it, and I agreed to make sure I
14 placed that information in front of your
15 working group. He was hopeful that you would
16 consider the information and discuss it at
17 your meeting next week. I said I could not
18 make any promises in that regard, but I would
19 commit to making sure that you had his
20 submitted information before you. So just for
21 your information I have not yet received it,
22 but as soon as I have it, you will, and the
23 working group will be so notified ^ access it.

24 **MR. PRESLEY:** Well, thank you, Larry. We
25 also had a briefing with Senator Harry Reid

1 from Nevada last Wednesday. Arjun was there.
2 We advised his staff of what was going on on
3 this, and I think we made them happy and will
4 be in the meeting in St. Louis. That's all I
5 have.

6 **DR. ZIEMER:** Very good. Robert, you were
7 able to get to the meeting?

8 **MR. PRESLEY:** Yes, sir.

9 **DR. ZIEMER:** And I know a number of others
10 were aligned to at least participate. Did
11 some others get there by phone as well?

12 **MR. PRESLEY:** No, sir.

13 **MR. CLAWSON:** Yes, I did, Bob, remember?

14 **MR. PRESLEY:** That's right.

15 **DR. ZIEMER:** Right, I knew Brad was hoping
16 to be there. And SC&A, Arjun was there --

17 **DR. MAKHIJANI:** Yeah.

18 **DR. ZIEMER:** Any others?

19 **MR. PRESLEY:** John Mauro was on the phone.

20 **DR. ZIEMER:** Oh, very good, okay, excellent.

21 **DR. BRANCHE:** Procedures Review, Ms. Munn.

22 **MS. MUNN:** We have a pretty heavy duty
23 schedule in front of the Procedures. As usual
24 there's a great deal going on there. We have
25 only one meeting scheduled at this moment.

1 That meeting is scheduled in Cincinnati ^ at
2 that time. We're going to be working from our
3 new revised matrix. And this will require a
4 little fancy footwork on our part, but we
5 expect that to work well. We're very pleased
6 that Nancy Adams has started to come on board
7 to give us a hand with some of the tracking
8 mechanisms. As you know the number of items
9 with which we deal are growing rather than
10 reducing in number as we ^ additional sets of
11 procedure reviews. It's very helpful to have
12 someone like Nancy able to follow some of the
13 less obvious directions that these take once
14 we have ^. I had intended to have before you
15 prior to this telephone call a transmission
16 letter to the Secretary to transmit the report
17 which SC&A had put together with respect to
18 the first set of procedures that we've worked
19 with for over a year. All of you received a
20 copy of that procedure draft during our last
21 face-to-face full Board meeting. And I would
22 anticipate that if you have comments with
23 respect to that document, you get them to me
24 prior to the work group meeting that is
25 scheduled on the 20th because we will look at

1 that again, and it's my expectation to have a
2 draft letter ready for the work group to
3 peruse at that time. So if you've not had an
4 opportunity to look at the report that SC&A
5 has put together on that first set of
6 procedures which you have in hand, but would
7 you please take an opportunity after our call
8 to look at it and send any comments that you
9 have back to me so that we can deal with it in
10 the work group.

11 One of the large new issues that we
12 will be facing on the 20th will be our first
13 undertaking to review TBD-6000 and -6001.
14 Those are the umbrella TBDs that ^ issues
15 facing so many of the ^ AWEs and other
16 contractors which were ^ in the early years.
17 The one which has been given the most
18 attention at this point is General Steel.
19 We've had considerable information ^ with
20 respect to Appendix BB ^ or TBD-6000. That
21 appendix deals with what transpired at General
22 Steel and especially with the use of the
23 Betatron machine ^ . This is not the only
24 site that we're going to encounter issues with
25 the Betatron ^ doubly important for us ^

1 exposure ^ in terms of ^ capability ^ dose
2 reconstructions that involve that particular ^
3 while we've been doing that. We've had long
4 conversations with Senator Obama's staffer,
5 Robert Stephan. Robert has asked for a
6 briefing ^ the SC&A report ^ General Steel and
7 that Betatron specifically. John, would you
8 like to make some comment with respect to the
9 conversation that we had with Robert?

10 **DR. MAURO:** Well, basically Robert just
11 wanted some clarification. The report that we
12 submitted has been PA cleared and Robert has a
13 copy and ^. And it's a very technical report.
14 I don't know if Bob Anigstein is on the line.

15 **DR. ANIGSTEIN:** I am.

16 **DR. MAURO:** He's the coauthor, and we spent
17 some time just, Bob Anigstein in essence ^
18 down the special findings where our ^ were
19 causing some differences between what we're
20 looking at the dose reconstruction for workers
21 at General Steel associated with the Betatron
22 and other activities, and how our analyses
23 differ from ^ NIOSH in Appendix BB. ^ go into
24 a little more detail about what that is, what
25 actually was the essence of it. And we will

1 be discussing this matter, in fact, the very
2 same materials during our upcoming Procedures
3 meeting.

4 I believe, Wanda, you had indicated
5 you will be setting aside some time to talk
6 about that issue.

7 **MS. MUNN:** Yes, I had hoped Bob Anigstein
8 would give us about a 15-minute presentation
9 on where we are with respect to your findings.
10 What that actually means in terms of our
11 ability to follow through with Betatron issues
12 especially.

13 **DR. ANIGSTEIN:** I will be there.

14 **MS. MUNN:** Thank you, Bob. We were on the
15 phone with Robert Stephan for more than an
16 hour and a half, very close to a two-hour
17 telephone call. I believe that he and the
18 senator are at this moment happy with where we
19 are. They wish things were moving faster, but
20 they'd like very much to ^ very careful
21 approach to ^ this information which is going
22 to carry on for other sites as well even at
23 the least, Los Alamos. So I think we're okay.

24 Unless anyone else has some comment
25 with respect to where we are on Procedures,

1 and where we expect to go, that's essentially
2 the ^.

3 **DR. ZIEMER:** Thank you, Wanda.

4 **DR. BRANCHE:** Rocky Flats site profile and
5 special exposure cohort petition, Mr. Griffon,
6 Chair.

7 **MR. GRIFFON:** Yeah, Christine, I think I
8 gave my update earlier. We're going to have -
9 -

10 **DR. BRANCHE:** Oh, that's right --

11 **MR. GRIFFON:** -- I'll e-mail soon that we're
12 going to have another work group meeting prior
13 to the St. Louis meeting. And I'll circulate
14 possible dates for a phone call meeting and
15 try to get all the parties available.

16 **DR. BRANCHE:** Forgive me, you're absolutely
17 right. I'm sorry, Mark.

18 **MR. GRIFFON:** That's fine.

19 **DR. BRANCHE:** Special exposure cohort issues
20 group including 250-day issue and preliminary
21 review of 8314 SEC petition, Dr. Melius,
22 Chair.

23 (no response)

24 **DR. BRANCHE:** Dr. Melius, if you're muted,
25 we can't hear you.

1 **DR. MELIUS:** No, I'm just unmuting myself.
2 I just got an e-mail saying there was supposed
3 to be a press conference now I didn't know
4 about.

5 But this is the 250 day issue, and we
6 just got an updated report from SC&A which I
7 will be distributing to the work group and
8 will be setting up a conference call hopefully
9 before the St. Louis meeting.

10 **DR. ZIEMER:** Thank you.

11 **DR. BRANCHE:** Savannah River site profile,
12 Mr. Griffon, Chair.

13 **MR. GRIFFON:** At this point we have not
14 reconvened that work group. It's a little
15 lower on the priority list unfortunately, but
16 we will get back to it. So no update right
17 now.

18 **DR. ZIEMER:** Okay, go ahead.

19 **DR. BRANCHE:** Use of Surrogate Data, if Dr.
20 Melius is still on the line.

21 **DR. MELIUS:** Yes, I am. I'm back on, sorry.
22 The surrogate data issue we actually were
23 supposed to meet yesterday, but that had to be
24 postponed, and we have a meeting of the work
25 group set up on June 9th I believe it is.

1 **DR. BRANCHE:** Yes, it is June 9th.

2 **DR. MELIUS:** Yep.

3 **DR. ZIEMER:** Okay.

4 **MS. MUNN:** That's a telecon, right?

5 **DR. MELIUS:** That will be a teleconference,
6 yes, at a decent hour.

7 **MS. MUNN:** Yes, thank you very much.

8 **DR. BRANCHE:** And then last but not least,
9 Worker Outreach, Mr. Gibson, Chair.

10 **MR. GIBSON:** Yeah, Dr. Ziemer, we're still
11 monitoring OCAS and they're in the process of
12 modifying the procedure in their database
13 dealing with worker outreach. And the only
14 other thing, there was a meeting April 22nd
15 down in Portsmouth with some of the guards,
16 OCAS and Kathy DeMers and myself were there to
17 meet with them.

18 They shared a lot of information that
19 OCAS wants to go back and look at. And also
20 expressed interest in a Portsmouth working
21 group. And I believe that probably at one of
22 our future meetings there will be some of them
23 attending and perhaps requesting the Board to
24 establish a working group for Portsmouth.

25 **DR. ZIEMER:** Okay, very good.

1 **DR. BRANCHE:** Dr. Ziemer, forgive me. They
2 haven't had a chance to meet, but I did not
3 mention Pinellas with Mr. Schofield as the
4 Chair.

5 **MR. SCHOFIELD:** Yes.

6 **DR. ZIEMER:** Go ahead.

7 **MR. SCHOFIELD:** I hope tomorrow or Friday
8 morning to issue three proposed dates to see
9 if we can all get together in Cincinnati for
10 the first face-to-face to go over the
11 preliminary matrix that has been issued by
12 SC&A.

13 **DR. ZIEMER:** Okay, you're getting underway
14 at least, right?

15 **MR. SCHOFIELD:** Yes.

16 **DR. ZIEMER:** Very good. Thank you very
17 much. I think that's all the work groups, is
18 it not?

19 **DR. BRANCHE:** That is correct.

20 **DR. ZIEMER:** While we're talking work
21 groups, let me --

22 **MR. GIBSON:** Dr. Ziemer?

23 **DR. ZIEMER:** Yes.

24 **MR. GIBSON:** There is the Santa Susana
25 working group, but there's nothing to report

1 at this time.

2 **DR. ZIEMER:** Ah, yes.

3 **DR. BRANCHE:** Forgive me. You're right.

4 **DR. ZIEMER:** Let's see. Do we have a
5 report?

6 **DR. BRANCHE:** He just said that there is no
7 report. Mr. Gibson is the Chair. He said
8 there is no report.

9 **DR. ZIEMER:** Okay, very good. On the issue
10 of work groups, John Howard of NIOSH, the
11 Director of NIOSH, has asked me to provide him
12 with a description of the duties of each of
13 the work groups, and I've started working on
14 this. And as I've gotten into it, I've
15 realized that it would be helpful to have
16 input from each of the chairs.

17 I'm talking about a description of
18 about three sentences that describes what you
19 might call the charter of the work group.
20 Now, we don't charter work groups quite in the
21 way that we do formally the subcommittees.
22 But nonetheless, it's appropriate that when a
23 work group be established, it have what you
24 might call a charge or a statement of its
25 responsibilities.

1 So what I would like each of the work
2 group chairmen to do, and if you would do this
3 in the next two weeks it would be very
4 helpful, is to sit down, write about three or
5 four sentences which you think describe what
6 your work group is or should be doing. For
7 example, it might be something if it's a site-
8 specific work group that you are reviewing,
9 responsible to review, for example, the site
10 profile of such and such or the SEC petition
11 from such and such and to make recommendations
12 to the Board.

13 It can be fairly simple. There may be
14 some particular nuances for your particular
15 work group. You don't have to go into great
16 detail, but in brief summary sentences, if you
17 would each describe to me what you believe
18 your work group's responsibility is. I will
19 then edit those and prepare a final list for
20 John Howard.

21 **DR. BRANCHE:** Dr. Ziemer, was there a
22 deadline given by Dr. Howard?

23 **DR. ZIEMER:** No, there was no deadline, and
24 the request came down through channels to me.
25 And I have indicated to him that I am in the

1 process of preparing this. And I think it
2 will be helpful if each work group chairman
3 has some input on it so that what we state is
4 really accurate.

5 **MR. ELLIOTT:** This is Larry Elliott. This
6 is also something that we have been needing in
7 order to post on the website the charges that
8 have been given to the working groups. So I
9 hope we can utilize --

10 **DR. ZIEMER:** Whatever we prepare for Dr.
11 Howard, we would make available then so the
12 website has some clarity on what the work
13 groups' sort of scope of work is.

14 **DR. ROESSLER:** This is Gen. What I'm
15 hearing is that this is a ^ site-specific work
16 group status a little bit more than just a
17 general description of what we're doing, but
18 probably pointing out some --

19 **DR. ZIEMER:** Well, I think, I don't
20 necessarily think that you should describe
21 every detailed issue unless you can do it
22 somewhat broadly. I mean, what would it look
23 like if you had this description sort of at
24 the front end.

25 Obviously, many work groups are well

1 into their work and you don't necessarily want
2 to describe every little nuance of every
3 little issue and string that you've pulled.
4 But I would keep it somewhat brief. I'm
5 thinking of a few sentences. Okay?

6 **DR. ROESSLER:** We'll give it a try.

7 **DR. LOCKEY:** Hey, Paul, Jim Lockey. One of
8 my work groups is completed. The other's
9 inactive, so I don't have to give you
10 anything, right?

11 **DR. ZIEMER:** I think we would consider the
12 work group on SEC petitions not qualified as
13 having completed their work, and therefore, no
14 longer in operation. So they don't need
15 anything. But the other one --

16 **DR. LOCKEY:** That's the conflict of
17 interest, but the Legal people said to hold
18 off on that.

19 **DR. ZIEMER:** Yeah, I guess as long as it's
20 not an active work group we're not going to
21 be, yeah, I would say, no, we don't need that.

22 **DR. LOCKEY:** Good.

23 **DR. BRANCHE:** Dr. Ziemer, this is Christine
24 Branche. Actually for the one that completed
25 its work, the fact that, I think actually a

1 short description of what the group actually,
2 what their task was --

3 **DR. ZIEMER:** What it was?

4 **DR. BRANCHE:** -- and what they accomplished
5 would probably be helpful because it's still
6 going to be on the website.

7 **DR. ZIEMER:** Oh, okay, but the website does
8 or will indicate the work is completed, right?

9 **DR. BRANCHE:** Yes.

10 **DR. ZIEMER:** Okay, I guess, Jim, we're
11 asking for a brief description then.

12 **DR. LOCKEY:** I heard that.

13 **DR. BRANCHE:** Sorry, Dr. Lockey.

14 **DR. ZIEMER:** We don't want you to get off
15 too easy.

16 **MS. MUNN:** But it really is important that
17 completed activities be shown.

18 **DR. ZIEMER:** Yeah, yeah.

19 **MR. CLAWSON:** Well, and also, this is Brad.
20 You know, not that Dr. Lockey doesn't have
21 enough to do already, but the thing is, is we
22 may have petitions that come in that do not
23 qualify. And it's important for them to know
24 that we go through the steps to be able to
25 make sure that we're covering it.

1 **DR. ZIEMER:** Right. Okay, so that will be
2 very helpful. So I appreciate getting those
3 if you can in the next two weeks.

4 **SELECTION OF BOARD CONTRACTOR**

5 Next we have update on the selection
6 of the Board contractor. And I guess we need
7 to see if David Staudt is on the line. He
8 wasn't on earlier I don't believe.

9 **DR. BRANCHE:** No, but he and I have
10 discussed, this is Christine. He and I have
11 discussed things, and actually things are on
12 track. There was one stage that David Staudt
13 needed to go through to make certain that all
14 potential applicants could, would be eligible
15 to apply for the funding, put in their
16 applications rather for the contract.

17 And so you may recall that I announced
18 that a mid-May announcement was anticipated,
19 and it is. I believe it was Mr. Griffon and
20 Mr. Clawson asked to see the language of the
21 contract request one more time. I expect that
22 you'll receive that in the next few days. And
23 then after you've received it, if there are no
24 edits, it should go out in the next couple of
25 days.

1 DR. ZIEMER: ^

2 DR. BRANCHE: I'm sorry. Dr. Ziemer?

3 DR. ZIEMER: That is the update?

4 DR. BRANCHE: That is the update.

5 DR. ZIEMER: Let me ask if there's any
6 questions that follow up on that.

7 (no response)

8 **TRACKING SYSTEMS**

9 DR. ZIEMER: If not, let's go on to the next
10 item about tracking systems being developed by
11 Nancy Adams. Last month, more specifically on
12 the 24th of April, I sent everyone a message
13 indicating that Nancy Adams has been asked to
14 help us track various issues and to help
15 establish databases as appropriate.

16 In that memo I had identified with
17 Nancy's help a number of areas where we would
18 anticipate databases. Some of these in a
19 sense really do already exist, the Procedures,
20 Dose Reconstruction Reviews, SEC Reviews, Site
21 Profile Reviews, Overarching Science Issues,
22 Board Housekeeping Issues. And then I
23 indicated that some of these may be broken
24 down further. But I asked that you be
25 thinking about information needs of your

1 groups and anticipate hearing from Nancy.

2 Also, Nancy and I are planning to have
3 a brainstorming session which Nancy's waiting
4 for me to initiate, and I haven't had an
5 opportunity to do that in terms of my own
6 schedule yet. But she and I are going to talk
7 a bit about what some of these things might
8 look like. But as we proceed here, and then
9 as Nancy contacts the various chairs of the
10 work groups to make sure that we're
11 anticipating your needs, I just want to sort
12 of give you a heads up that this is coming.

13 Make sure that if you have issues
14 either in how we aren't doing something or how
15 we should do something different that you
16 provide that input to Nancy. I don't know if
17 Nancy's on the line today, is she?

18 **DR. BRANCHE:** She's right here.

19 **DR. ZIEMER:** Oh, good. Nancy, you may have
20 some additional comments at this time then
21 maybe we'll take a moment and see if there are
22 questions from Board members.

23 **MS. ADAMS:** The plan is to take the existing
24 format that has been developed by SC&A for
25 Wanda's Procedures group and to modify that to

1 the extent possible for use in tracking these
2 other areas so that the look and feel of all
3 of the tracking systems is essentially the
4 same. And that folks don't, therefore, need
5 to learn and get familiar with a number of
6 different systems.

7 I've had an opportunity to go through
8 the Procedures database and do some initial
9 finding if you will of some of the information
10 which I've put together a really rudimentary
11 spreadsheet and shared that with Wanda
12 yesterday. And based on her and my discussion
13 I think, at least for the start, we seem to be
14 in agreement that this is something useful.
15 It's something that, at least for right now
16 it's a starting point.

17 So I have not contacted any of the
18 other work group members as yet. I thought
19 that it might be better to do that after this
20 call, and also, in an environment where I can
21 look at them face to face rather than trying
22 to deal with this kind of amorphous issue over
23 this amorphous telephone line. So anyway
24 that's where we are.

25 **DR. ZIEMER:** Okay, thank you, Nancy.

1 Board members, do any of you have any
2 questions or comments at this time? This will
3 help guide you to some extent streamline and
4 standardize some of the methods of tracking.

5 **MR. CLAWSON:** Paul, this is Brad Clawson.
6 So are we going to be trying to use this
7 instead of the matrix or what?

8 **DR. ZIEMER:** Well, actually, this is just a
9 variation of the matrix. It basically takes
10 the matrix and puts it in a form where you can
11 track each of the issues readily. It's not, I
12 wouldn't look at it as something different
13 than the matrix but a, if it works out right,
14 a more user friendly version of the matrix.

15 **MS. MUNN:** What Nancy's put together so far
16 that she and I have been talking about is
17 essentially a summation of each of the detail
18 pieces of the complicated matrix so that the
19 casual user can look at it quickly and get a
20 feel for the magnitude of the work that has
21 been done, and what has yet to be done. Where
22 we are at any given point in time which is
23 difficult to do with a matrix especially the
24 matrix we're dealing with in Procedures which
25 is extremely complex and very bulky.

1 **DR. ZIEMER:** But in essence what the system
2 looks like at the top is the matrix. And then
3 for any item in that matrix, if you click on
4 it at the appropriate spot, you can find when
5 you dealt with that item, what was done with
6 it, if there's follow-up going on, who's
7 responsible for what, how it was resolved. So
8 it has a number of levels of detail. But
9 basically it is the matrix in a form that
10 allows tracking of the issues in a manner that
11 hopefully doesn't allow things to fall through
12 the cracks.

13 **MR. CLAWSON:** And I understand that, and
14 maybe it's just from me looking at the
15 Procedure one. Because, you know, it's very
16 well put together. I'm not meaning anything
17 by that, but, boy, it is, there's a lot of
18 stuff on there, and it's a little bit hard to
19 get around.

20 **DR. ZIEMER:** Yeah, I think probably what
21 we'd have to do is to take a matrix from a
22 particular site, either an SEC or a site
23 profile matrix, and look at that and see what
24 the product would look like.

25 **MR. CLAWSON:** This is what I was learning.

1 We're starting out with Pinellas coming up
2 here, and I'm not speaking for Mr. Schofield
3 who's a, maybe we ought to start running it
4 through that system to see where --

5 **DR. ZIEMER:** We probably need a prototype to
6 try it out with, and if that works well, we
7 can transfer it to others as well. But that's
8 a good suggestion.

9 **MS. MUNN:** When you're dealing with a site
10 profile, however, when in most cases you have
11 a maximum of a couple of dozen issues at most,
12 in most cases seven to ten, but then in the
13 matrix there's much, the matrix we're working
14 with in Procedures is much less complicated
15 for that number of issues than it is where
16 you're dealing --

17 **DR. ZIEMER:** Well, it depends on the site,
18 of course. Some site profiles the matrix is
19 extremely complex.

20 **MS. MUNN:** Yes, they can be. The can be
21 certainly.

22 **DR. ZIEMER:** But we'll need to try it out
23 and see how it works.

24 **MS. MUNN:** Right.

25 **MR. CLAWSON:** That was just a suggestion.

1 And by the way, Wanda, my Fernald is almost
2 about 30 or 40 so...

3 **MS. MUNN:** Yeah, right, right. But that's a
4 long way from 150.

5 **DR. ZIEMER:** Okay, thanks for that comment.
6 Any other comments?

7 **MS. ADAMS:** It would be beneficial if folks
8 would bring or even electronically transmit to
9 me the latest versions of their matrix.
10 Although I think going into this the thought
11 was not necessarily to produce a tracking
12 system for each of the work groups but only
13 for those six kind of bucket areas work
14 groups. That's the dose reconstruction issues
15 and the procedures issues.

16 **MR. CLAWSON:** Well, to me that's a little
17 bit different than what we just said then. Am
18 I understanding this right? This is, well, my
19 understanding of what you just told me was
20 that we're still going to use a matrix but
21 just for major items or what?

22 **DR. ZIEMER:** I'm not sure we know the answer
23 to that at this point.

24 **MR. CLAWSON:** Okay, well, we'll work through
25 it.

1 **MS. MUNN:** And this is Wanda. Some of the
2 thinking that went into what we were doing in
3 Procedures, Brad, was that if it lent itself
4 well to site profiles, then the advantage that
5 the process has that we're using now is that
6 it provides such an excellent archive when
7 it's all over, more so probably than the
8 matrix process that we used originally.

9 That original process which seemed to
10 work well for me for site profiles, is a very,
11 it served for me to be a very good method for
12 keeping track of where we were going at any
13 given time. But when it was all done, that
14 matrix format didn't always give the kind of
15 archive and information a year later that the
16 process we have adopted and Procedures is
17 doing. So from an archive point of view it's
18 very appropriate if it appears that the site
19 is going to require that depth of process. So
20 my guess is this may end up being a site-by-
21 site, a case-by-case issue.

22 **DR. ZIEMER:** Right. In answer to Nancy's
23 question about the various matrices and asking
24 for their availability, I think most of them
25 are already on the website, are they not? Or

1 are some of them restricted to the O drive?
2 I'm trying to remember.

3 **MS. MUNN:** Well, one of the concerns that we
4 had was that some of the matrix material not
5 being fully cleared.

6 **DR. ZIEMER:** Well, right, but in some form.
7 I'm just thinking in terms of Nancy taking an
8 early look at the matrices. I can provide
9 them to you, Nancy. I think you probably want
10 to take a look at them and see what, sort of
11 what they look like and how they would lend
12 themselves to this kind of tracking. Is that
13 correct?

14 **MS. ADAMS:** Yes. I have some that I got
15 from Kathy Behling and the SC&A staff, but I
16 don't know that I have them all.

17 **DR. ZIEMER:** Okay, well, we'll make sure you
18 get at least a good number of them and that
19 you can begin to look at and evaluate.

20 So anyway, that kind of gives us an
21 update on what we're doing there and
22 hopefully, this will be a way of streamlining,
23 and as I say maybe to some extent,
24 standardizing how we're doing the tracking of
25 issues and tracking of information and issue

1 resolution.

2 **MR. CLAWSON:** I understand that, too, Paul.
3 So what I'm wondering is when we're
4 transferring these matrices back and forth,
5 you know, to NIOSH and SC&A and everything, do
6 you want us to put Nancy on our list so she
7 could be looking at them or --

8 **DR. ZIEMER:** I think that would be helpful
9 for the time being if you could make sure
10 Nancy gets a copy of these.

11 Nancy, is that agreeable?

12 **MS. ADAMS:** Absolutely.

13 **MR. SCHOFIELD:** Nancy, this is Phil
14 Schofield. I've got a quick question. Do you
15 want these cross-referenced to the TBD
16 documents and the site profiles?

17 **MS. ADAMS:** Right now I would take them
18 however you're using them so I can compare
19 them to how other people are using them to
20 look at commonalities and differences. I
21 don't want to create any more work for anybody
22 than what you're already doing at least at
23 this point.

24 **DR. ZIEMER:** In fact, the ideal would be to
25 minimize that if there's a standard way to do

1 there be some kind of net in place to see that
2 we don't lose any of those issues. And that's
3 one of the benefits of Nancy's approach. And
4 then as Wanda had mentioned earlier, this
5 issue of being able to make summary statements
6 to judge where we are in terms of completeness
7 of activities within a particular work group.
8 So those are things that we're trying to
9 accomplish with this analysis as well. Thank
10 you.

11 **DR. ZIEMER:** Right, thanks Lew, well said.

12 Any other comments on this?

13 (no response)

14 **REVIEW LOCKEY VOTES FROM APRIL MEETING**

15 **DR. ZIEMER:** Okay, let's move on. We have
16 really a reporting item. Dr. Lockey was not
17 able to be present at our last meeting, but we
18 had a number of votes which were
19 recommendations to the Secretary which under
20 our rules require us to obtain the votes of
21 those not present.

22 So Dr. Branche, if you want to report,
23 please, on the Lockey votes.

24 **DR. BRANCHE:** That's going to be my
25 pleasure. Dr. Ziemer and I spoke with Dr.

1 Lockey on Tuesday, April 22nd, having provided
2 to him in advance all of the petition
3 documents or the petition statements that
4 outlined what the Board voted on in advance.

5 Dr. Lockey's votes were obtained on
6 those presentations that were made during the
7 April Board meeting, specifically, Special
8 Alloy Metals which is SAM Laboratories at
9 Columbia University, Horizons, Inc. in
10 Cleveland, Ohio, Telex Pierpont in Jersey
11 City, New Jersey, NUMEC Park Township in
12 Pennsylvania, and Sandia National Laboratory,
13 Livermore, which was a vote left over from our
14 January 2008 meeting.

15 All of those the Board voted
16 unanimously on all the petitions save his
17 vote. After having read the drafts during the
18 call with Dr. Lockey and providing some
19 additional background, Dr. Lockey concurred
20 with each vote on the motions rendered by the
21 Board in his absence.

22 Also, when I described the
23 recommendation of the Dose Reconstruction
24 Subcommittee in a letter to the HHS Secretary
25 summarizing the fourth set be sent through the

1 Board on behalf of the subcommittee, Dr.
2 Lockey concurred with that approach as well.
3 Thank you.

4 **DR. ZIEMER:** Thank you, and just for the
5 record, that vote on Dose Reconstructions was,
6 I believe, actually on the fourth and fifth
7 set taken together. Is that not correct?
8 Mark, are you still on the line?

9 **MR. GRIFFON:** Yeah, I believe that's
10 correct.

11 **DR. ZIEMER:** Because it was a set of 40
12 cases.

13 **MR. GRIFFON:** Yes.

14 **DR. ZIEMER:** Sixty through 100, so that
15 would have been the fourth and fifth set, and
16 a single vote.

17 **DR. BRANCHE:** Oh, I understand. I didn't
18 understand that's how it went so thank you for
19 clarifying that.

20 **DR. ZIEMER:** So that's the update on Dr.
21 Lockey's votes.

22 I believe that completes the items on
23 our agenda.

24 **MALLINCKRODT VISIT**

25 **DR. BRANCHE:** Dr. Ziemer, this is Christine

1 again. I have one quick item, a logistical
2 item, regarding our meeting in St. Louis. I
3 asked a number of you if you were willing to
4 go to visit the Mallinckrodt site the day
5 before the meeting. Many of you said yes. I
6 just want to confer with a couple of the Board
7 chairs. I would ask that if you think you
8 would rather have a meeting or if you would
9 like to have an update of some sort prior to
10 our meeting and while we're in St. Louis, if
11 you could let me know in the next couple of
12 days, and I will schedule our visit to
13 Mallinckrodt accordingly.

14 As I said, it would be the day before
15 our meeting starts. And there are provisions
16 for us to be able to start our meeting mid-day
17 on the first full day of the meeting depending
18 upon whether or not you all want, several of
19 you want to have Board meetings.

20 **DR. ZIEMER:** You're talking about work group
21 meetings?

22 **DR. BRANCHE:** What did I say? I meant work
23 group meetings, excuse me. Nancy's looking at
24 me strangely because I'm saying the wrong
25 thing. I meant the work group meetings,

1 forgive me.

2 Then I'll confer with Dr. Ziemer
3 before I send out a draft agenda. But I know
4 that Mr. Presley said something about wanting
5 to have a meeting and so over the next couple
6 of weeks I think that some of you may want to
7 meet, and then I can set the times for the
8 agenda accordingly.

9 **DR. ZIEMER:** In that regard also for the
10 visit that was described to the Mallinckrodt
11 site, do we know how long that will take? I
12 think initially they were talking about doing
13 that in the morning. But in terms of travel
14 and so on some indicated a desire to do that
15 later in the day.

16 **DR. BRANCHE:** I'm looking now at early
17 afternoon, and I think it would take, I mean,
18 by the time we get out there, I believe it
19 takes about 45 minutes, half an hour to 45
20 minutes to get to the site. But my
21 understanding is that the site would take
22 about an hour to tour.

23 **DR. ZIEMER:** So it would be doable in the
24 afternoon, thus, allowing people to travel
25 Monday morning to St. Louis.

1 **DR. BRANCHE:** Exactly, Dr. Ziemer.

2 **DR. ZIEMER:** Okay, very good. That's
3 helpful.

4 Any other items in terms of our
5 meeting times or other housekeeping issues,
6 Dr. Branche?

7 **DR. BRANCHE:** No, not at this time, thank
8 you.

9 **MR. PRESLEY:** Hey, Paul, this is Bob
10 Presley. I've got a question. On the tour I
11 understood that all this thing was going to be
12 was to go visit a monument.

13 **DR. BRANCHE:** No, it's a tour of a facility
14 that isn't very large and the monument is part
15 of the facility that, the tour and the
16 facility rather, the facility houses both the
17 site that would be toured as well as the
18 monument.

19 **MR. PRESLEY:** Okay, so there is something to
20 see.

21 **DR. BRANCHE:** Yes, I wouldn't take you on a
22 rabbit trail.

23 **DR. ZIEMER:** Any other questions or
24 comments?

25 (no response)

1
2
3
4
5
6
7
8
9

DR. ZIEMER: Anything else for the good of the order?

(no response)

DR. ZIEMER: If not, I will declare the meeting adjourned, and thank you all very much for your participation.

(Whereupon, the meeting was adjourned at 12:25 p.m.)

1

CERTIFICATE OF COURT REPORTER**STATE OF GEORGIA****COUNTY OF FULTON**

I, Steven Ray Green, Certified Merit Court Reporter, do hereby certify that I reported the above and foregoing on the day of May 14, 2008; and it is a true and accurate transcript of the testimony captioned herein.

I further certify that I am neither kin nor counsel to any of the parties herein, nor have any interest in the cause named herein.

WITNESS my hand and official seal this the 11th day of June, 2008.

STEVEN RAY GREEN, CCR, CVR-CM, PNSC
CERTIFIED MERIT COURT REPORTER
CERTIFICATE NUMBER: A-2102